Literature DB >> 1583143

Comparison of commercially available media for detection and isolation of Ureaplasma urealyticum and Mycoplasma hominis.

N L Broitman1, C M Floyd, C A Johnson, L M de la Maza, E M Peterson.   

Abstract

The Mycotrim Triphasic flask system (Irvine Scientific, Irvine, Calif.) was compared with a system composed of Mycotrim GU broth (Irvine Scientific) and A7 or A8 agar (Remel, Lenexa, Kans.) for the ability to detect Ureaplasma urealyticum and Mycoplasma hominis from 129 genital specimens. Of the 64 specimens positive for U. urealyticum, 25, 98, and 100% were detected on Mycotrim Triphasic agar and A7 and A8 agars, respectively. All 18 specimens that grew M. hominis were detected by A7 and A8 agars, and 94% grew on Mycotrim Triphasic agar. Mycotrim GU broth detected all of the positive specimens, and Mycotrim Triphasic broth detected all but one. Mycotrim GU broth inoculated simultaneously with either A7 or A8 agar was found to be more sensitive and cost-effective than the Mycotrim Triphasic flask system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1583143      PMCID: PMC265280          DOI: 10.1128/jcm.30.5.1335-1337.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Mycoplasma hominis and Ureaplasma urealyticum. Comparison of media for isolation and prevalence among patients with nongonococcal nonchlamydial genital infections.

Authors:  S Cavicchini; M R Biffi; A Brezzi; E Alessi
Journal:  G Ital Dermatol Venereol       Date:  1989 Jul-Aug       Impact factor: 2.011

Review 2.  Infections and male fertility.

Authors:  E Megory; H Zuckerman; Z Shoham; B Lunenfeld
Journal:  Obstet Gynecol Surv       Date:  1987-05       Impact factor: 2.347

3.  Evaluation of Mycotrim-GU for isolation of Mycoplasma species and Ureaplasma urealyticum.

Authors:  J C Wood; R M Lu; E M Peterson; L M de la Maza
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

4.  Isolation of Mycoplasma species and Ureaplasma urealyticum from obstetrical and gynecological patients by using commercially available medium formulations.

Authors:  L E Phillips; K H Goodrich; R M Turner; S Faro
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

5.  Effects of manganese on the growth and morphology of Ureaplasma urealyticum.

Authors:  J A Robertson; M H Chen
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

6.  Comparative evaluation of media for isolation of ureaplasma urealyticum and genital mycoplasma species.

Authors:  D S Leland; M A Lapworth; R B Jones; M L French
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

7.  Evaluation of PPLO, A7B, E, and NYC agar media for the isolation of Ureaplasma urealyticum and Mycoplasma species from the genital tract.

Authors:  D M Yajko; E Balston; D Wood; R L Sweet; W K Hadley
Journal:  J Clin Microbiol       Date:  1984-01       Impact factor: 5.948

8.  Significance of appropriate techniques and media for isolation and identification of Ureaplasma urealyticum from clinical specimens.

Authors:  R B Kundsin; A Parreno; S Poulin
Journal:  J Clin Microbiol       Date:  1978-10       Impact factor: 5.948

9.  Enhancement of Ureaplasma urealyticum growth on a differential agar medium (A7B) by a polyamine, putrescine.

Authors:  M C Shepard; R S Combs
Journal:  J Clin Microbiol       Date:  1979-12       Impact factor: 5.948

10.  Comparison of media for isolation of Ureaplasma urealyticum and genital Mycoplasma species.

Authors:  V Fiacco; M J Miller; E Carney; W J Martin
Journal:  J Clin Microbiol       Date:  1984-11       Impact factor: 5.948

  10 in total
  1 in total

1.  Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial.

Authors:  Ian Boostrom; Yohan Bala; Jelena Minic Vasic; Jelena Gluvakov; Emmanuel Chanard; Andrew H Barratt; Kirsty Sands; Edward Portal; Laurence Devigne; Lucy C Jones; Owen B Spiller
Journal:  J Antimicrob Chemother       Date:  2021-11-12       Impact factor: 5.790

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.